Mixed Lineage Kinase

Mixed lineage kinases (MLKs) are mitogen activated protein kinase kinase kinases (MAPKKKs) with features of both serine-threonine and tyrosine kinases that regulate the c-Jun N-terminal kinase (JNK) mitogen activated protein kinase (MAPK) signaling cascade, and also regulate p38 and extracellular signal-regulated kinase (ERK).

MLK3 (MAP3K11) is the most widely expressed MLK family member, and is expressed in neurons (as well as other cell types). At the cellular level, MLK3 is activated by stress, including reactive oxygen species, ceramide, and TNFα. At the molecular level, it is activated by Cdc42 and Rac, which interact with MLK3, and can cause it to dimerize via a leucine zipper interface, resulting in autophosphorylation and enzyme activation.

Products Related to Mixed Lineage Kinase(11)

GC15004 URMC-099
CAS: 1229582-33-5
Purity: >99.50%
URMC-099, as a 7‐azaindole‐based MLK3 inhibitor with IC 50 of 14 nM, could specifically affect specific Aβ species engaged in disease pathobiology.
GC34140 TC13172
CAS: 2093393-05-4
Purity: >99.00%
TC13172 is a mixed lineage kinase domain-like protein (MLKL) inhibitor with an EC50 value of 2 nM for HT-29 cells.
GC36203 GW806742X
CAS: 579515-63-2
Purity: >99.50%
GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K D of 9.3μM.
GC61454 GW806742X hydrochloride
Purity: >98.50%
GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis.
GC63680 MLKL-IN-2
CAS: 899759-16-1
Purity: >98%
MLKL-IN-2 is a MLKL inhibitor extracted from patent WO2021224505A1, compound (i).
GC64634 MLK-IN-1
CAS: 1627729-62-7
Purity: >98%
MLK-IN-1 is a potent, brain penetrant and specific mixed lineage kinase 3 (MLK-3) inhibitor, compound 68, extracted from patent US20140256733A1.
GC69543 NecroIr1
Purity: >98%
NecroIr1 is an iridium (III) complex that induces necrosis in cisplatin-resistant lung cancer cells (A549R). NecroIr1 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr1 can activate receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL), regulating CDK4 expression.
GC69544 NecroIr2
Purity: >98.00%
NecroIr2 is an iridium (III) complex that induces necrosis in cisplatin-resistant lung cancer cells (A549R). NecroIr2 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr2 can activate receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL), regulating CDK4 expression.
GC72756 (E/Z)-Necrosulfonamide
CAS: 432531-71-0
Purity: >98.00%
(E/Z)-Necrosulfonamide is a racemic compound of Necrosulfonamide.
GC73424 PRT062607 acetate
CAS: 1370261-98-5
Purity: >99.00%
PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis.
GC78969 WJH-C19
Purity: >98.50%
WJH-C19 is an orally active RIPK1 inhibitor with an IC 50 of 5.7 nM.

Category Product List
Catalog No.	Product Name	CAS No.	Purity
GC15004	URMC-099	1229582-33-5	>99.50%
GC15004	URMC-099, as a 7‐azaindole‐based MLK3 inhibitor with IC 50 of 14 nM, could specifically affect specific Aβ species engaged in disease pathobiology.
GC34140	TC13172	2093393-05-4	>99.00%
GC34140	TC13172 is a mixed lineage kinase domain-like protein (MLKL) inhibitor with an EC50 value of 2 nM for HT-29 cells.
GC36203	GW806742X	579515-63-2	>99.50%
GC36203	GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K D of 9.3μM.
GC61454	GW806742X hydrochloride	-	>98.50%
GC61454	GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis.
GC63680	MLKL-IN-2	899759-16-1	>98%
GC63680	MLKL-IN-2 is a MLKL inhibitor extracted from patent WO2021224505A1, compound (i).
GC64634	MLK-IN-1	1627729-62-7	>98%
GC64634	MLK-IN-1 is a potent, brain penetrant and specific mixed lineage kinase 3 (MLK-3) inhibitor, compound 68, extracted from patent US20140256733A1.
GC69543	NecroIr1	-	>98%
GC69543	NecroIr1 is an iridium (III) complex that induces necrosis in cisplatin-resistant lung cancer cells (A549R). NecroIr1 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr1 can activate receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL), regulating CDK4 expression.
GC69544	NecroIr2	-	>98.00%
GC69544	NecroIr2 is an iridium (III) complex that induces necrosis in cisplatin-resistant lung cancer cells (A549R). NecroIr2 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr2 can activate receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL), regulating CDK4 expression.
GC72756	(E/Z)-Necrosulfonamide	432531-71-0	>98.00%
GC72756	(E/Z)-Necrosulfonamide is a racemic compound of Necrosulfonamide.
GC73424	PRT062607 acetate	1370261-98-5	>99.00%
GC73424	PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis.
GC78969	WJH-C19	-	>98.50%
GC78969	WJH-C19 is an orally active RIPK1 inhibitor with an IC 50 of 5.7 nM.